AbbVie (ABBV) Price Target Lowered to $235 at Evercore ISI

Sultan Khalid

Tue, May 19, 2026 at 9:06 AM EDT 2 min read

AbbVie Inc. (NYSE:ABBV) is included among the Top 12 Undervalued Dividend Stocks to Buy Now.

AbbVie Inc. (NYSE:ABBV) is a research-based biopharmaceutical company that engages in the research and development, manufacturing, commercializing, and sale of medicines and therapies worldwide.

On May 15, Evercore ISI slightly trimmed its price target on AbbVie Inc. (NYSE:ABBV) from $236 to $235, but maintained its ‘Outperform’ rating on the shares. The lowered target, which still indicates an upside of over 12% from the current price level, comes after the company reported mixed results for its Q1 last month.

AbbVie Inc. (NYSE:ABBV) reported adjusted earnings of $2.65 per share for the first quarter, falling slightly below estimates by $0.02. However, its revenue grew by over 12% YoY to $15 billion and exceeded estimates by $280 million. The strong revenue growth was driven by the demand for the company’s newer immunology drugs Skyrizi and Rinvoq, as ‌it continues to move beyond former top-selling treatment Humira.

AbbVie Inc. (NYSE:ABBV) also raised its full-year 2026 adjusted EPS guidance to ⁠a range ​of $14.08 to $14.28, from $13.96 to $14.16 previously. Moreover, the company now expects total net revenues of approximately $67.3 billion for the year, up from its prior forecast of around $67 billion.

While we acknowledge the potential of ABBV as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 12 Best Blue Chip Dividend Stocks to Buy Now and 11 Best Rising Dividend Stocks to Buy Right Now

Disclosure: None. Follow Insider Monkey on Google News.